Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Exelixis Inc.
Sponsor

Exelixis Inc.

United States 220 East Grand Avenue, 94080-4811, United States

About the sponsor

Research activity centers on advanced clear cell renal cell carcinoma, non-clear cell renal cell carcinoma, and broader metastatic renal cell carcinoma, with attention to treatment settings spanning first-line through later-line care. The portfolio also includes bladder cancer and urothelial carcinoma, including both ICI-naïve and ICI-experienced disease.

  • Advanced clear cell renal cell carcinoma
  • Non-clear cell renal cell carcinoma
  • Urothelial carcinoma
  • Bladder cancer

These studies reflect sustained interest in kidney and urinary tract cancers, with emphasis on difficult-to-treat metastatic disease.

About Specializations

Exelixis Inc. runs clinical trials in conditions such as Hormone-refractory prostate cancer, Pancreatic neuroendocrine tumour, Neoplasm malignant, Neoplasm, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

10 clinical trials

Pancreatic neuroendocrine tumour

Recruiting

A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Exelixis Inc.

Neoplasm malignant+7

Recruiting

Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Exelixis Inc.

Renal cell carcinoma

Not yet recruiting

Study comparing XL092 plus nivolumab versus sunitinib for patients with advanced or metastatic non-clear cell kidney cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Exelixis Inc.

Squamous cell carcinoma of head and neck

Not recruiting

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Exelixis Inc.

Medullary thyroid cancer

Not recruiting

Comparison of two doses of cabozantinib (60 mg vs 140 mg) in patients with progressive metastatic medullary thyroid cancer

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Colorectal cancer metastatic

Not recruiting

Study Comparing XL092 and Atezolizumab with Regorafenib for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Exelixis Inc.

Hormone-refractory prostate cancer

Not recruiting

Study of Cabozantinib and Atezolizumab Compared to Hormonal Therapy in Adults with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Exelixis Inc.

Study of cabozantinib with atezolizumab compared to sorafenib in untreated patients with advanced liver cancer (hepatocellular carcinoma)

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Exelixis Inc.

Renal cancer metastatic

Not recruiting

Study on Cabozantinib, Nivolumab, and Ipilimumab for Patients with Advanced or Metastatic Kidney Cancer Who Have Not Received Prior Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Thyroid cancer

Not recruiting

Study of Cabozantinib in Adults with Progressive Thyroid Cancer Who Did Not Respond to Previous Treatment with Radioactive Iodine and VEGFR Therapy

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.